Clinical trial · Interventional
Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.
NCT04205864CI-TRIAL-00045813completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel matrix used and not used during pelvic lymph node dissection.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrium Cancer | — | UNRESOLVED | — |
| Lymphocele | — | UNRESOLVED | — |
| Lymphocele After Surgical Procedure | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional Pelvic lymphadenectomy | Procedure | — | UNRESOLVED |
| Thrombi-Gel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Conventional pelvic lymphadenectomy
- description
- Conventional pelvic lymphadenectomy
- interventionNames
- Procedure: Conventional Pelvic lymphadenectomy
- type
- EXPERIMENTAL
- label
- Thrombin gel matrix pelvic lymphadenectomy
- description
- Thrombin gel matrix applicated after conventional pelvic lymphadenectomy
- interventionNames
- Drug: Thrombi-Gel
Primary outcomes (1)
- measure
- Frequency of pelvic lymphocele
- timeFrame
- post-operative 2th month
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Endometrial cancer patients who need laparotomic bilateral PLND * Patients suitable for surgery Exclusion Criteria: * Previous pelvic surgery * Previous Chemotherapy or Radiotherapy * Patients who undergo only lymph node sampling * Patients who have not signed Informed Consent
References
Publications (1)
- BACKGROUNDKim YH, Shin HJ, Ju W, Kim SC. Prevention of lymphocele by using gelatin-thrombin matrix as a tissue sealant after pelvic lymphadenectomy in patients with gynecologic cancers: a prospective randomized controlled study. J Gynecol Oncol. 2017 May;28(3):e37. doi: 10.3802/jgo.2017.28.e37. Epub 2017 Feb 28. PMID 28382800